Israel’s Institute for Biological Research IIBR (see here previously) has stated that it has delivered 1,000 doses of its BriLife coronavirus vaccine to Georgia for starting Phase 2 trials. IIBR’s partner, NRx, will lead the trials, expand patient numbers and … Continue reading →

Israel’s IIBR-developed BriLife vaccine (see here previously – now in Phase 2 testing) has advantages over vaccines such as Pfizer and Moderna. It recognizes the whole of the spike protein and can be easily adjusted to protect against mutations. https://www.youtube.com/watch?v=KJCGLJoqh5o

The Israel Institute for Biological Research (IIBR) (see here previously) has signed an agreement with Israeli-founded NRx Pharmaceuticals. NRx will complete Phase 2 / 3 trials and commercialize IIBR’s “BriLife” COVID vaccine. Clinical trials will be completed in the Ukraine, … Continue reading →

Israel’s Institute for Biological Research (IIBR) anticipates commencing Phase 3 of its coronavirus vaccine trials soon – probably in Argentina as 30,000 unvaccinated volunteers are required. A new trial may also be launched to test if the two-shot vaccine could … Continue reading →

The Covid-19 vaccine being developed by the Israel Institute for Biological Research (IIBR) is beginning Phase 1 human trials. Head of IIBR, Professor Shapira confirmed this at the recent Christian Media zoom Summit attended by this newsletter editor, who asked … Continue reading →

The Israel Institute for Biological Research (IIBR) in Ness Ziona has just completed the patent application process for eight new coronavirus antibodies (reported here previously). https://www.jpost.com/health-science/iibr-files-for-patents-for-8-coronavirus-antibodies-628134 http://www.israelnationalnews.com/News/News.aspx/280294